

**Centre for AIDS Reagents**

**Data Sheet**

<b>REPOSITORY REFERENCE:</b>	<b>ARP1192</b>
<b>NAME:</b>	SHIV-1157ipEL-p, harvest day 9
<b>CHARACTERISTICS:</b>	SHIV-1157ipEL-p is a tier 1 R5 Clade C SHIV. It is a chimera of the "early" neutralization sensitive SHIV-1157ip envelope and the "late" engineered backbone of SHIV-1157ipd3N4, which was engineered to have extra NF-KB sites in the LTRs. The envelope gene was derived from a relatively recently transmitted paediatric R5 Clade C isolate from Zambia. SHIV-1157ipEL-p is a biological isolate that is exclusively R5 tropic and mucosally transmissible. It causes T-cell depletion during acute infection and gradual progression to AIDS. SHIV-1157ipEL-p has been used as a challenge virus in passive and active immunization studies.
<b>SPECIAL CHARACTERISTICS:</b>	TCID <sub>50</sub> = 3.2 x 10 <sup>5</sup> /ml p27 conc. (ng/ml) = 407
<b>PROVIDED:</b>	0.5ml
<b>CELL LINE FOR PROPAGATION:</b>	RM PBMC
<b>STORAGE:</b>	Vapour phase of LN2
<b>SOURCE:</b>	Dr. Ruth Ruprecht, Dana Farber Cancer Institute and NIAID, DAIDS.
<b>REFERENCES:</b>	<p>Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, Kramer VG, Lakhashe S, Santosuosso M, Poznansky MC, Novembre FJ, Villinger F, Else JG, Montefiori DC, Rasmussen RA, Ruprecht RM. R5 Clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. <i>PLoS One</i>. 2010 Jul 21;5(7):e11689. PubMed PMID: 20657739</p> <p>Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, Xu W, Whitney JB, Goins LM, Ong H, Li PL, Shai-Kobiler E, Wang T, McCann CM, Zhang H, Wood C, Kankasa C, Secor WE, McClure HM, Strobert E, Else JG, Ruprecht RM. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV Clade C Env. <i>J Virol</i>. 2006 Sep;80(17):8729-38. PMID: 16912320</p> <p>Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK, Wang W, Novembre FJ, Villinger F, Ibegbu C, Patel K, Corti D, Agatic</p>

**National Institute for Biological Standards and Control – Assuring the quality of biological medicines**

Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG United Kingdom  
Tel +44 (0)1707 641000 Fax +44 (0)1707 641050 www.nibsc.ac.uk  
A World Health Organization Laboratory for Biological Standards



G, Vanzetta F, Bianchi S, Heeney JL, Sallusto F, Lanzavecchia A, Ruprecht RM. An anti-HIV-1 V3 loop antibody fully protects cross-Clade and elicits T-cell immunity in macaques mucosally challenged with an R5 Clade C SHIV. *PLoS One*. 2011 Mar 31;6(3):e18207. PubMed PMID: 21483815

Lakhashe SK, Velu V, Sciaranghella G, Siddappa NB, Dipasquale JM, Hemashettar G, Yoon JK, Rasmussen RA, Yang F, Lee SJ, Montefiori DC, Novembre FJ, Villinger F, Amara RR, Kahn M, Hu SL, Li S, Li Z, Frankel FR, Robert-Guroff M, Johnson WE, Lieberman J, Ruprecht RM. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 Clade C SHIV challenges. *Vaccine*. 2011 Aug 5;29(34):5611-22. Epub 2011 Jul 14. PubMed PMID:21693155

Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, Hu SL, Villinger F, Else JG, Novembre FJ, Yoon JK, Lee SJ, Montefiori DC, Ruprecht RM, Rasmussen RA. Vaccination against heterologous R5 Clade C SHIV: prevention of infection and correlates of protection. *PLoS One*. 2011;6(7):e22010. Epub 2011 Jul 20. PubMed PMID: 21799765

#### **ACKNOWLEDGEMENTS:**

Publications should acknowledge the donor of the reagent and the Centre for AIDS Reagents. Suggested wording can be found on our website in the "Acknowledgement" section at:-

[www.nibsc.ac.uk/spotlight/centre\\_for\\_aids\\_reagents.aspx](http://www.nibsc.ac.uk/spotlight/centre_for_aids_reagents.aspx)

Please also ensure that you send us a copy of any papers resulting from work using reagents acquired through CFAR, this can be by e-mail or printed copy.